Supplementary Table 5. Univariate analyses of CSC markers. HR = hazard ratio; 95% CI = 95 percent confidence interval.

|  |  |  |  |
| --- | --- | --- | --- |
|   | **Loco-regional control** | **Distant metastases** | **Overall survival** |
|   | **HR (95% CI)** | **p-value** | **HR (95% CI)** | **p-value** | **HR (95% CI)** | **p-value** |
| **All patients** |  |  |  |  |  |  |
| *MET*  | 5.19 (1.97-13.7) | **0.001** | 3.41 (1.61-7.23) | **0.001** | 2.74 (1.60-4.70) | **<0.001** |
| *SLC3A2*  | 6.54 (1.97-21.7) | **0.002** | 4.17 (1.74-10.0) | **0.001** | 2.37 (1.36-4.13) | **0.002** |
| *CD44*  | 3.56 (1.36-9.35) | **0.010** | 1.69 (0.83-3.43) | 0.149 | 1.57 (0.92-2.67) | 0.098 |
| CD44 | 9.09 (1.24-66.8) | **0.030** | 2.29 (0.90-5.86) | 0.084 | 1.78 (0.91-3.50) | 0.093 |
| **Patients with HPV16 DNA-negative tumors only** |  |  |  |
| *MET*  | 3.74 (1.29-10.9) | **0.015** | 2.82 (1.16-6.87) | **0.023** | 2.42 (1.27-4.61) | **0.007** |
| *SLC3A2*  | 9.23 (1.25-68.1) | **0.029** | 3.56 (1.08-11.7) | **0.037** | 1.53 (0.79-2.98) | 0.206 |
| *CD44*  | 4.15 (1.25-13.8) | **0.020** | 1.69 (0.72-3.94) | 0.225 | 1.40 (0.76-2.58) | 0.284 |
| CD44 | - | \* | 2.20 (0.53-9.18) | 0.281 | 1.45 (0.58-3.64) | 0.426 |

\*As there were no events in the CD44 protein negative group, the Cox model did not converge.